interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Berdazimer Sodium

Generic competition · all medicines · read 12 November 2026

Is there a generic of Berdazimer Sodium, and who makes it?

Berdazimer Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Berdazimer Sodium1 dosage-form group in the Orange Book
0generic makers listed
  1. Berdazimer Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Gel, Topical

Brand listed, no generic listed as marketed

Brand listed as marketed: Zelsuvmi. No generic is listed as marketed.

202020252030203501brand 2024data datePatent 9737561 listed to expire 20 August 2030Patent 10376538 listed to expire 20 August 2030Patent 9526738 listed to expire 3 September 2031Patent 9289442 listed to expire 3 July 2032Patent 10265334 listed to expire 3 July 2032Patent 9855211 listed to expire 27 February 2034Patent 11285098 listed to expire 28 February 2034Patent 10258564 listed to expire 22 November 2034Patent 11723858 listed to expire 10 July 2035Patent 11040006 listed to expire 10 July 2035Patent 10736839 listed to expire 10 July 2035Patent 10322081 listed to expire 10 July 2035Exclusivity NCE to 5 January 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 5 January 2029Exclusivity NCE Zelsuvmi
  • 20 August 2030Patent 9737561
  • 20 August 2030Patent 10376538 drug product
  • 3 September 2031Patent 9526738 drug product
  • 3 July 2032Patent 9289442 drug product
  • 3 July 2032Patent 10265334 drug product
  • 27 February 2034Patent 9855211 drug product
  • 28 February 2034Patent 11285098 drug product
  • 22 November 2034Patent 10258564

4 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.